Europe Restricts Cyproterone Use Due To Meningioma Risk; Companies To Conduct Studies
Executive Summary
The risk of developing meningioma with cyproterone-containing medicines is rare, but it is serious enough to merit restrictions on how such products are used, according to the European Medicines Agency.